Approach resulted in transfusion independence and durable anemia response
Momelotinib, a new JAK inhibitor, inches closer to market approval
Dose-finding trial adds to evidence of efficacy
Interim results of phase 2 trial are promising
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy